Potential new treatments for type 2 diabetes

Trends in Pharmacological Sciences

Volumn 21, Issue 7, 2000, Pages 259-265

  Bailey, Clifford J ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 4 (4 METHYLCYCLOHEXYL) 4 OXOBUTYRIC ACID; 5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; 5 [2 (2 NAPHTHYLMETHYL) 5 BENZOXAZOLYLMETHYL] 2,4 THIAZOLIDINEDIONE; 5 [4 [2 (1 INDOLYL)ETHOXY]BENZYL] 2,4 THIAZOLIDINEDIONE; 9 (2 FLUORO 1 METHYLPROPYL) 2 METHOXY 6 (1 PIPERAZINYL)PURINE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; ANTIOBESITY AGENT; BM 15 2054; DARGLITAZONE; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; INSULIN; LY 83281; METFORMIN; MITIGLINIDE; N (2 BENZOYLPHENYL) O [2 (METHYL 2 PYRIDINYLAMINO)ETHYL]TYROSINE; NETOGLITAZONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TROGLITAZONE; TT 501; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

DIET SUPPLEMENTATION; DISEASE COURSE; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; ISLETS OF LANGERHANS; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0034235964     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(00)01506-6     Document Type: Review

References (75)

1. Amos A.F.et al. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabetic Med. 14:1997;S1-S85.
2. DeFronzo R.A. Pathogenesis of type 2 diabetes. metabolic and molecular implications for identifying diabetes genes Diabetes Rev. 5:1997;177-269.
3. Polonsky K.S.et al. Non-insulin dependent diabetes mellitus. A genetically programmed failure of the B cell to compensate for insulin resistance. New Engl. J. Med. 334:1996;777-783.
4. Groop L.C.et al. Glucose and free fatty acid metabolism in non-insulin dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin. Invest. 84:1989;205-213.
5. Nathan D.M. Long-term complications of diabetes mellitus. New Engl. J. Med. 328:1993;1676-1685.
6. Brownlee M. Glycation and diabetic complications. Diabetes. 43:1994;836-841.
7. Vlassara H. Recent progress in advanced glycation end products and diabetic complications. Diabetes. 46:1997;S19-S25.
8. Reaven G.M. Pathophysiology of insulin resistance in human disease. Physiol. Rev. 75:1995;473-486.
9. Bailey C.J. Insulin resistance and antidiabetic drugs. Biochem. Pharmacol. 58:1999;1511-1520.
10. DeFronzo R.A. Pharmacologic therapy for type 2 diabetes mellitus. Ann. Intern. Med. 131:1999;281-303.
11. Lebovitz H.E. α-Glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Rev. 6:1998;132-145.
12. Lebovitz H.E. Insulin secretagogues. old and new Diabetes Rev. 7:1999;139-153.
13. Bailey C.J., Turner R.C. Metformin. New Engl. J. Med. 334:1996;574-579.
14. Howlett H.C.S., Bailey C.J. A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Safety. 20:1999;489-503.
15. Day C. Thiazolidinediones. a new class of antidiabetic drugs Diabetic Med. 16:1999;1-14.
16. Edelman S.V., Henry R.R. Insulin therapy for normalizing glycosylated haemoglobin in type II diabetes. Application, benefits and risks. Diabetes Rev. 3:1995;308-334.
17. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care. 18:1995;258-268.
18. UK Prospective Diabetes Study 16. Overview of 6 years therapy of type II diabetes: a progressive disease. Diabetes. 44:1998;1249-1258.
19. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 352:1998;837-853.
20. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 352:1998;854-865.
21. Wing R.et al. Long-term effects of modest weight loss in type II diabetic patients. Arch. Intern. Med. 147:1987;1749-1753.
22. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br. Med. J. 317:1998;703-713.
23. Standl E. Cardiovascular risk in type 2 diabetes. Diabetes Obesity Metab. 1:1999;S24-S36.
24. Wild S.H. Glycaemic control and cardiovascular disease in type 2 diabetes. a review Diabetes Metab. Rev. 15:1999;197-204.
25. Spiegelman B.M. PPAR-γ adipogenic regulator and thiazolidinedione receptor Diabetes. 46:1998;507-514.
26. Buckingham R.E.et al. Peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes. 47:1998;1326-1334.
27. Saleh Y.M.et al. Metabolic and vascular effects of the thiazolidinedione troglitazone. Diabetes Rev. 7:1999;55-76.
28. Patel J.et al. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes. a twelve-week randomised, placebo-controlled study Diabetes Obesity Metab. 1:1999;165-172.
29. Arakawa K.et al. Actions of novel antidiabetic thiazolidinedione, T-174, in animal models of non-insulin dependent diabetes mellitus (NIDDM) and in cultured muscle cells. Br. J. Pharmacol. 125:1998;429-436.
30. Upton R.et al. Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker diabetic fatty (ZDF) rats treated with the thiazolidinedione, MCC-555. Br. J. Pharmacol. 125:1998;1708-1714.
31. Murakami K.et al. A novel insulin snesitizer acts as a coligand for peroxisome proliferator-activated receptor-α (PPAR-α) and PPAR-γ Diabetes. 47:1998;1841-1847.
32. Furnsinn C.et al. Chronic and acute effects of thiazolidinediones BM13.1258 and BM15.2054 on rat skeletal muscle glucose metabolism. Br. J. Pharmacol. 128:1999;1141-1148.
33. Tenasaki J.et al. Role of JTT-501, a new insulin sensitizer, in restoring impaired GLUT4 translocation in adipocytes of rats fed a high fat diet. Diabetologia. 41:1998;400-409.
34. Brown K.K.et al. A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-γ reverses diabetic phenotype of the Zucker diabetic fatty rat. Diabetes. 48:1999;1415-1424.
35. Loviscach M.et al. Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue. relation to insulin action Diabetologia. 43:2000;304-311.
36. Forman B.M.et al. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ Proc. Natl. Acad. Sci. U. S. A. 94:1997;4312-4317.
37. Hotamisligil G.S.et al. Tumor necrosis factor α a key component of the obesity-diabetes link Diabetes. 43:1994;1271-1278.
38. Tanaka T.et al. Down regulation of peroxisome proliferator activated-receptor γ expression by inflamatory cytokines and its reversal by thiazolidinediones. Diabetologia. 42:1999;702-710.
39. Souza S.C.et al. BRL 49653 blocks the lipolytic actions of tumor necrosis factor-α. A potential new insulin-sensitizing mechanism for thiazolidinediones. Diabetes. 47:1998;691-695.
40. Murase K.et al. Pioglitazone time dependently reduces tumour necrosis factor α level in muscle and improves metabolic abnormalities in Wistar fatty rats. Diabetologia. 41:1998;257-264.
41. Cohen N.et al. Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin dependent diabetes mellitus. J. Clin. Invest. 95:1995;2501-2509.
42. Tsiani E.et al. Vanadium compounds. Biological actions and potential as pharmacological agents. Trends Endocrinol. Metab. 8:1997;51-58.
43. Tsiani E.et al. Tyrosine phosphatase inhibitors, vanadate and pervanadate stimulate glucose transport and GLUT translocation in muscle cells by a mechanism independent of phosphatidylinositol 3-kinase and protein kinase C. Diabetes. 47:1998;1676-1686.
44. Reul B.A.et al. Effects of vanadium complexes with organic ligands on glucose metabolism. a comparison study in diabetic rats Br. J. Pharmacol. 126:1999;467-477.
45. Evans J.L.et al. Protein tyrosine phosphatases. their role in insulin action and potential as drug targets Expert Opin. Invest. Drugs. 8:1999;139-160.
46. Wrobel J.et al. PTP1B inhibition and antihyperglycemic activity in the ob/ob mouse model of novel 11-arylbenzo(b)-naphtho(2,3-d)furans and 11-arylbenzo(b)-naphtho(2,3-d)thiophenes. J. Med. Chem. 42:1999;3199-3202.
47. Strack V.et al. Serine residues 994 and 1023/25 are important for insulin receptor kinase inhibition by protein kinase C isoforms β2 and θ Diabetologia. 43:2000;443-449.
48. Zhang B.et al. Discovery of a small molecule insulin mimetic with antidiabetic activity in mice. Science. 284:1999;974-977.
49. Krook A.et al. Characterization of signal transduction and glucose transport in skeletal muscle from type 2 diabetic patients. Diabetes. 49:2000;284-292.
50. Le Roith D. Insulin-like growth factors. New Engl. J. Med. 336:1997;633-640.
51. Bailey C.J. New pharmacological approaches to glycemic control. Diabetes Rev. 7:1999;94-113.
52. Carvalto C.R.O.et al. Effect of captopril, losartan, and bradykinin on early steps of insulin action. Diabetes. 46:1997;1950-1957.
53. Dunning B.E. New non-sulfonylurea insulin secretagogues. Expert Opin. Invest. Drugs. 6:1997;1041-1048.
54. + channels and insulin secretion. their role in health and disease Diabetologia. 42:1999;903-919.
55. Drucker D.J. Glucagon-like peptides. Diabetes. 47:1998;159-169.
56. Holst J.J., Deacon C.F. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes. 47:1998;1663-1670.
57. Xu W.et al. Exendin-4 stimulates both B-cell replication and neogenesis, resulting in increased B-cell and improved glucose tolerance in diabetic rats. Diabetes. 48:1999;2270-2276.
58. Bailey C.J. New insulin secretagogues. Diabetes Rev. Int. 7:1998;2-7.
59. Ueno N.et al. Erythromycin improves glycaemic control in patients with type 2 diabetes mellitus. Diabetologia. 43:2000;411-415.
60. Scheen A.J., Lefebvre P.J. Management of the obese diabetic patient. Diabetes Rev. 7:1999;77-93.
61. Hollander P.A.et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomised double-blind study. Diabetes Care. 21:1998;1288-1294.
62. Finer N.et al. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes. a randomized, double-blind, placebo-controlled study Diabetes Obesity Metab. 2:2000;1-8.
63. Widdowson P.S. The development of new antiobesity drugs and the impact of leptin. Chem. Ind. 1:1997;55-58.
64. Boss O.et al. Uncoupling proteins 2 and 3. Potential regulators of mitochondrial energy metabolism. Diabetes. 49:2000;143-156.
65. Young A.A. Amylin's physiology and its role in diabetes. Curr. Opin. Endocrinol. Diabetes. 4:1997;282-290.
66. Magnesium supplementation in the treatment of diabetes. Diabetes Care. 15:1992;1065-1067.
67. Anderson R.A.et al. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes. 46:1997;1786-1791.
68. Stahl W., Sies H. Antioxidant defense: vitamins E and C and carotenoids. Diabetes. 46:1997;S14-S18.
69. Bailey C.J. New drugs for the treatment of diabetes mellitus. Alberti K.G.M.M. International Textbook of Diabetes Mellitus (2nd edn). 1997;865-881 John Wiley & Sons.
70. Foley J.R. Rationale and application of fatty acid oxidation inhibitors in treatment of diabetes mellitus. Diabetes Care. 15:1992;773-784.
71. Lee W.L., Zinman B. From insulin to insulin analogs. progress in the treatment of type l diabetes Diabetes Rev. 6:1998;73-88.
72. Ricordi C. Human islet transplantation. new perspectives for an old challenge Diabetes Rev. 4:1996;356-369.
73. McClenaghan N.H.et al. Engineering cultured insulin-secreting pancreatic B-cell lines. J. Mol. Med. 77:1999;235-243.
74. Bailey C.J.et al. Prospects for insulin delivery by ex-vivo somatic cell gene therapy. J. Mol. Med. 77:1999;244-249.
75. Leibowitz G., Levine F. Gene therapy for type 1 and 2 diabetes. Diabetes Rev. 7:1999;124-138.